Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infections -- Qualified Infectious ...

Scientists have developed an injectable or catheter-administered hydrogel with enhanced capabilities for treating hepatocellular carcinoma, a deadly form of liver cancer. This drug-eluting hydrogel ...

Relationship of angiotensin II receptor blocker (ARB) to the effectiveness of immune checkpoint blockade (ICB) in non-small-cell lung cancer (NSCLC) and inhibition of angiotensin II/AGTR1 signaling in ...

Geographic disparities in brachytherapy accessibility for cervical cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text component.

OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company developing ...

Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 ...